Synthetic Lethality — A New Direction in Cancer-Drug Development  

Oleh:

Iglehart, J. Dirk ; Silver, Daniel P.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 361 no. 02 (Jul. 2009), page 189-191 .

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2009.04 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Creating drugs that selectively kill cancer cells without harming normal cells is notoriously difficult for several reasons. First, oncogenes that are overexpressed in cancer cells are usually identical to, or mutated in ways that make them only subtly different from, their normal counterparts. For this reason, the development of treatment specifically targeting oncogenes in tumors is difficult. Furthermore, the products of tumor-suppressor genes with low or absent activity in tumors as a result of mutation are elusive pharmacologic targets — it is hard to restore an absent activity pharmacologically.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali